What's new on therapies for elevated lipoprotein(a)

Natalie C Ward^{1

2}, Carl J Schultz^{2

3}, Gerald F Watts^{2

4}

Affiliations

¹ a School of Public Health, Faculty of Health Sciences , Curtin University , Perth , Australia.
² b School of Medicine, Faculty of Health and Medical Sciences , University of Western Australia , Perth , Australia.
³ c Department of Cardiology , Royal Perth Hospital , Perth , Australia.
⁴ d Lipid Disorders Clinic , Royal Perth Hospital , Perth , Australia.

Editorial

Natalie C Ward et al. Expert Rev Clin Pharmacol. 2019 Jun.

. 2019 Jun;12(6):495-499.

doi: 10.1080/17512433.2019.1610391. Epub 2019 Apr 30.

Natalie C Ward^{1

2}, Carl J Schultz^{2

3}, Gerald F Watts^{2

4}

¹ a School of Public Health, Faculty of Health Sciences , Curtin University , Perth , Australia.
² b School of Medicine, Faculty of Health and Medical Sciences , University of Western Australia , Perth , Australia.
³ c Department of Cardiology , Royal Perth Hospital , Perth , Australia.
⁴ d Lipid Disorders Clinic , Royal Perth Hospital , Perth , Australia.

No abstract available

Keywords: Lipoprotein (a); PCSK9 inhibitors; antisense oligonucleotides; atherosclerotic cardiovascular disease; lipids.

Publication types